James Hazel - ImpediMed Independent Non-Executive Director
| IPDQF Stock | USD 0.06 0.02 26.69% |
Director
Mr. James Thomas Hazel B.Ec F Fin FAICD serves as Independent NonExecutive Director of ImpediMed Limited. Hazel chairs the Audit and Risk Committee and serves on the Remuneration Committee and Nomination Committee. Jim had an extensive career in retail and investment banking and was formerly Chief General Manager of Adelaide Bank Limited. Jim is a Director of Bendigo Adelaide Bank Limited Rural Bank Limited Centrex Metals Limited Coopers Brewery Limited and Motor Accident Commission. Jim is the Chairman of the Board of Ingenia Communities Group. Jims areas of experience include finance and accounting ASX listed companies former CEO chairman of audit committees and corporate governance. since 2006.
| Age | 60 |
| Tenure | 18 years |
| Phone | 61 7 3860 3700 |
| Web | https://www.impedimed.com |
ImpediMed Management Efficiency
The company has return on total asset (ROA) of (0.2848) % which means that it has lost $0.2848 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5192) %, meaning that it generated substantial loss on money invested by shareholders. ImpediMed's management efficiency ratios could be used to measure how well ImpediMed manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 |
ImpediMed Limited Leadership Team
Elected by the shareholders, the ImpediMed's board of directors comprises two types of representatives: ImpediMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImpediMed. The board's role is to monitor ImpediMed's management team and ensure that shareholders' interests are well served. ImpediMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImpediMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David BS, Ex Director | ||
| Michael Schreiber, VP of Global Commercialization | ||
| Timothy Cruickshank, Chief Officer | ||
| Leanne Ralph, Company Secretary | ||
| Michael Panaccio, Independent Non-Executive Director | ||
| Shashi Tripathi, CTO COO | ||
| Walton Taylor, Medical Director | ||
| Scott Ward, Director | ||
| Ann Holder, Senior Vice President - General Management & Operations | ||
| AAICD ACIS, Company Sec | ||
| Judith Downes, Non-Executive Director | ||
| Donald Williams, Non-Executive Director | ||
| Elizabeth Gaines, Non-Executive Director | ||
| Dennis Schlaht, VP Technology | ||
| Cherrell Hirst, Non-Executive Chairman of the Board | ||
| Thomas Schenk, Chief Officer | ||
| Catherine Kingsford, VP Affairs | ||
| Morten Vigeland, CFO | ||
| David Adams, Director | ||
| Frank Vicini, Chief Medical Officer | ||
| Nancy Deisinger, VP HR | ||
| Amit Patel, Non-Executive Director | ||
| Jack Cosentino, Chief Strategy Officer | ||
| Richard Carreon, CEO and President Managing Director and Executive Director | ||
| Michael Bassett, Sr Officer | ||
| Robert Graham, Non-Executive Director | ||
| Richard Valencia, MD CEO | ||
| Gary Goetzke, Non-Executive Director | ||
| James Hazel, Independent Non-Executive Director |
ImpediMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImpediMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.88) % | |||
| Operating Margin | (2.00) % | |||
| Current Valuation | 81.27 M | |||
| Shares Outstanding | 1.79 B | |||
| Shares Owned By Insiders | 13.73 % | |||
| Shares Owned By Institutions | 14.96 % | |||
| Price To Earning | (8.46) X | |||
| Price To Book | 2.74 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImpediMed Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for ImpediMed Pink Sheet analysis
When running ImpediMed's price analysis, check to measure ImpediMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImpediMed is operating at the current time. Most of ImpediMed's value examination focuses on studying past and present price action to predict the probability of ImpediMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImpediMed's price. Additionally, you may evaluate how the addition of ImpediMed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |